Willie R. Earley, MD

Signant Health, Plymouth Meeting, Pennsylvania (Sachs); Employee of Intra-Cellular Therapies, a Johnson & Johnson company, Bedminster, New Jersey

  • 6Articles
  • 25.3KReads
  • 2009–2026Active
  • 24Collaborators
  • 266Citations

About

Willie R. Earley, MD, affiliated with Intra-Cellular Therapies, A Johnson & Johnson company, in Bedminster, New Jersey, has contributed extensively to research published in Psychiatrist.com from 2009 to 2026. The work focuses on major depressive disorder (MDD), including studies on adjunctive treatments such as lumateperone and extended-release quetiapine, as well as investigations into sexual dysfunction and suicidality in this population. Additionally, Earley has published on child and adolescent psychiatry, specifically the use of quetiapine in bipolar I disorder mania. Frequent collaborators include Johan Szamosi, Suresh Durgam, and Anita H. Clayton.

Publications

JCP
Lumateperone as Adjunctive Therapy in Patients With Major Depressive Disorder and Anxious Distress
Original Research

Lumateperone as Adjunctive Therapy in Patients With Major Depressive Disorder and Anxious Distress

September 14, 2026

Adjunctive lumateperone 42 mg significantly improved depression and anxiety symptoms in patients with MDD with inadequate antidepressant response and anxious distress
, , , et al
JCP
Evaluation of Sexual Function With Adjunctive Lumateperone in Major Depressive Disorder
Original Research

Evaluation of Sexual Function With Adjunctive Lumateperone in Major Depressive Disorder

September 2, 2026

Adjunctive lumateperone 42 mg did not worsen sexual functioning and was not associated with treatment-related sexual dysfunction.
, , , et al
JCP
Lumateperone as Adjunctive Therapy in MDD: A Randomized, Double-Blind, Phase 3 Trial
Original Research

Lumateperone as Adjunctive Therapy in MDD: A Randomized, Double-Blind, Phase 3 Trial

August 25, 2025

In patients with MDD with inadequate antidepressant response, adjunctive lumateperone 42 mg significantly improved depression symptoms and severity versus adjunctive placebo, and it was generally well tolerated.
, , , et al
JCP
Original Research

Extended Release Quetiapine Fumarate in Patients With Major Depressive Disorder: Suicidality Data From Acute and Maintenance Studies

May 15, 2014

, , , et al
JCP
Article

Efficacy and Safety of Quetiapine in Children and Adolescents With Mania Associated With Bipolar I Disorder: A 3-Week, Double-Blind, Placebo-Controlled Trial

January 15, 2013

, , , et al
JCP
Original Research

Extended-Release Quetiapine as Adjunct to an Antidepressant in Patients With Major Depressive Disorder: Results of a Randomized, Placebo-Controlled, Double-Blind Study

April 7, 2009

, , , et al

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe